{"groups":[{"description":"Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.","id":"FG000","title":"Arm A: Abemaciclib Plus Fulvestrant"},{"description":"Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.","id":"FG001","title":"Arm B: Placebo Plus Fulvestrant"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"116"},{"groupId":"FG001","numSubjects":"128"}],"type":"On study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"21"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"182"},{"groupId":"FG001","numSubjects":"186"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"181"},{"groupId":"FG001","numSubjects":"185"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"37"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"142"},{"groupId":"FG001","numSubjects":"149"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Completers included participants who had an event (progressive disease or death) and participants who were off the treatment and were alive at study conclusion."}